Anchor Investment Management LLC Buys 893 Shares of AstraZeneca PLC (NASDAQ:AZN)

Anchor Investment Management LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 231.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,279 shares of the company’s stock after purchasing an additional 893 shares during the period. Anchor Investment Management LLC’s holdings in AstraZeneca were worth $100,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of AstraZeneca during the third quarter valued at about $4,822,000. Advisory Resource Group purchased a new position in AstraZeneca during the 3rd quarter valued at about $946,000. Rehmann Capital Advisory Group raised its position in AstraZeneca by 1.8% during the 3rd quarter. Rehmann Capital Advisory Group now owns 10,027 shares of the company’s stock valued at $788,000 after purchasing an additional 175 shares during the last quarter. Toronto Dominion Bank lifted its holdings in AstraZeneca by 15.5% in the 3rd quarter. Toronto Dominion Bank now owns 17,929 shares of the company’s stock worth $1,397,000 after buying an additional 2,408 shares during the period. Finally, Coldstream Capital Management Inc. grew its position in shares of AstraZeneca by 4.1% in the 3rd quarter. Coldstream Capital Management Inc. now owns 26,777 shares of the company’s stock worth $2,086,000 after buying an additional 1,050 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN opened at $66.58 on Friday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a market cap of $206.44 billion, a price-to-earnings ratio of 31.86, a price-to-earnings-growth ratio of 1.19 and a beta of 0.45. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a fifty day simple moving average of $70.18 and a two-hundred day simple moving average of $76.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the company posted $0.87 EPS. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. Research analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

AZN has been the subject of a number of recent analyst reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.